英格兰女性性健康门诊就诊者接种后HPV血清阳性率
该研究对2011至2015年英格兰六家性健康服务机构16至20岁女性的残留血清进行HPV16/18抗体检测,发现疫苗诱导血清阳性率随年龄从78.1%降至52.6%,且未发现二价HPV疫苗对生殖器疣的交叉保护效应。
要点
- 疫苗诱导血清阳性率随年龄增加而下降,16岁为78.1%,20岁为52.6%。
- 非英国出生、更贫困地区及有衣原体感染史的女性血清阳性率更低。
- 二价HPV疫苗对生殖器疣无显著交叉保护(调整OR 0.93,95%CI 0.74-1.18)。
核心结论
- 该高危人群疫苗诱导血清阳性率与普通人群接种覆盖率一致,但部分高危亚组更低。
- 本研究未提供证据支持HPV16/18疫苗对生殖器疣的交叉保护效应。
研究设计与样本
- 对2011至2015年英格兰六家性健康服务机构16至20岁女性的残留血清进行HPV16/18抗体检测。
- 采用病毒样颗粒多重血清学 assay,共收集3973份血清,其中3870份(97.4%)结果有效。
- 采用病例对照设计,比较有生殖器疣患者(537例)与匹配无疣患者(1515例)的疫苗诱导血清阳性率。
主要发现
- 疫苗诱导血清阳性率随年龄下降,16岁为78.1%,20岁为52.6%。
- 非英国出生、更贫困地区及有衣原体感染史的女性疫苗诱导血清阳性率更低。
- 不同族裔间接种率存在差异,但主要受贫困和国家出生地混杂影响。
- 病例对照分析显示二价HPV疫苗对生殖器疣无显著保护作用(调整OR 0.93;95%CI 0.74-1.18)。
关键数值与推荐
- 疫苗诱导血清阳性定义为同时HPV16和HPV18血清阳性,且至少一种型别抗体水平高或两种型别均中等高。
- 生殖器疣交叉保护分析调整比值比为0.93(95%CI 0.74-1.18)。
临床怎么用
- 血清学监测可用于评估HPV疫苗接种覆盖率,尤其在高危人群中。
- 对非英国出生、贫困地区及有衣原体感染史的女性应加强HPV疫苗接种和健康教育。
- 不应期望二价HPV疫苗通过交叉保护预防生殖器疣,需依赖其他防控措施。
局限性
- 研究使用残留血清,可能无法完全代表接种人群。
- 病例对照设计无法排除未测量混杂因素。
- 仅纳入16至20岁女性性健康门诊就诊者,结果外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The National HPV Immunisation Programme was introduced in England in September 2008 using the HPV16/18 bivalent vaccine. We conducted serological surveillance to explore vaccination coverage levels. We also conducted a case-control study to investigate a hypothesised cross-protective effect of the HPV16/18 vaccine against genital warts. METHODS: Residual serum specimens from 16 to 20 year-old women attending six specialist sexual health services (SSHS) between 2011 and 2015 in England were tested for antibodies against HPV16 and HPV18 using a virus-like particle (VLP)-based multiplex serology assay. Patients were classified as having vaccine-induced seropositivity if they were seropositive for both HPV types and either had high antibody levels for at least one HPV type, or moderately high levels for both HPV types. Differences in vaccine-induced seropositivity by patient characteristics were investigated using logistic regression. Vaccine-induced seropositivity was then compared for patients with genital warts (cases) and matched patients without (controls). RESULTS: Of 3,973 serum specimens collected, 3,870 (97.4%) had a valid result. The proportion of women with vaccine-induced seropositivity decreased with age (from 78.1% in 16-year-olds to 52.6% in 20-year-olds). Vaccine-induced seropositivity was lower among women born outside the UK, from more deprived areas and with a history of chlamydia diagnosis. A difference in uptake by ethnic group was also seen but this was largely confounded by differences in deprivation and country of birth. Among 537 cases and 1,515 controls, there was little evidence of a protective effect of the bivalent HPV vaccine against genital warts (adjusted odds ratio 0.93; 95% CI: 0.74-1.18). DISCUSSION: Vaccine-induced seropositivity in this high-risk population was in line with vaccination coverage in the general population although was lower in some at-risk sub-groups. This study does not provide evidence to support a cross-protective effect of the HPV16/18 vaccine against genital warts.
引用
- Mesher D, Thomas SL, Linley E, et al. Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England. Vaccine. 2021. PMID: 34127297. doi:10.1016/j.vaccine.2021.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。